Soft Tissue Sarcoma

Cabozantinib Plus Temozolomide: A Promising Dual-Pathway Approach for Advanced Leiomyosarcoma

By MedXY 02/18/2026

A phase 2 trial demonstrates that combining cabozantinib with temozolomide provides significant progression-free survival benefits for patients with advanced leiomyosarcoma, achieving a 74% 12-week PFS rate with a manageable safety profile, marking a potential new therapeutic strategy for soft tissue sarcomas.

news Oncology

Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma

By MedXY 01/20/2026

This Phase II trial evaluates first-line anlotinib plus anthracyclines and ifosfamide followed by anlotinib maintenance for advanced soft-tissue sarcoma, showing an objective response rate of 30.8% and a manageable safety profile, suggesting a promising new treatment strategy.

news Oncology Radiology

Streamlining Sarcoma Care: Five-Day Preoperative Radiation Matches Long-Term Efficacy of 5-Week Regimens

By MedXY 12/21/2025

A Phase 2 clinical trial reveals that an ultrahypofractionated 5-day preoperative radiation regimen for high-risk soft tissue sarcoma provides durable local control and favorable late-term toxicity compared to the conventional 5-week course, potentially revolutionizing the standard of care for patient convenience.

Hematology-Oncology news Ophthalmology

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

By MedXY 10/24/2025

Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.

news Oncology Specialties

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial

By MedXY 08/13/2025

The EREMISS trial demonstrates that regorafenib significantly prolongs progression-free survival as maintenance therapy after first-line doxorubicin chemotherapy in advanced non-adipocytic soft tissue sarcoma patients, with manageable safety profiles.